rxstat › Drug prices › Cipaglucosidase Alfa
Cipaglucosidase Alfa (Pombiliti) price in Canada
No current shortage
Cipaglucosidase Alfa 105 mg/vial powder for solution costs about $1751.75 per billed unit (often a pen or vial) on public drug plan price lists in Nova Scotia, before the pharmacy's dispensing fee.
Cipaglucosidase Alfa has no current shortage reported in Canada. No active reports are on file.
Price by province
| Strength and form | AB | NS |
|---|---|---|
| 105 mg/vial Powder For Solution | $1751.75/unitnot covered | $1751.75/unit |
| Plan coverage | Not covered | Special approval |
What you'll pay at the pharmacy
These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay.
Listed products by province
Alberta: 1 product
- Pombiliti 105 mg/vial Powder For Solution · BMI
Nova Scotia: 1 product
- Pombiliti 105 mg/vial Powder For Solution · AMT
Shortage status
No shortage or discontinuation reports have been filed with Health Canada for Cipaglucosidase Alfa. rxstat watches those reports through the day; sign up below to hear if that changes.
Common questions
How much does Cipaglucosidase Alfa cost in Canada?
Cipaglucosidase Alfa 105 mg/vial powder for solution costs about $1751.75 per billed unit (often a pen or vial) on public drug plan price lists in Nova Scotia, before the pharmacy's dispensing fee.
Is Cipaglucosidase Alfa covered by provincial drug plans?
On the public plans' own lists: Alberta: not covered; Nova Scotia: special approval. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Related drugs (other alimentary tract and metabolism products)
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.